Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Molecular architecture of native HIV-1 gp120 trimers.

Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S.

Nature. 2008 Sep 4;455(7209):109-13. doi: 10.1038/nature07159. Epub 2008 Jul 30.

2.

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG.

Nat Struct Mol Biol. 2008 Mar;15(3):312-7. doi: 10.1038/nsmb.1382. Epub 2008 Feb 10.

PMID:
18264114
3.

Inference of macromolecular assemblies from crystalline state.

Krissinel E, Henrick K.

J Mol Biol. 2007 Sep 21;372(3):774-97. Epub 2007 May 13.

PMID:
17681537
4.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20.

PMID:
17362988
5.

Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.

Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS.

Nature. 2006 Jan 5;439(7072):38-44.

PMID:
16397490
6.

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF.

J Mol Biol. 2005 Jul 1;350(1):126-44.

PMID:
15907931
7.

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.

Zhao X, Chen FP, Megaw AG, Sullender WM.

J Infect Dis. 2004 Dec 1;190(11):1941-6. Epub 2004 Oct 27.

PMID:
15529258
8.

Mortality associated with influenza and respiratory syncytial virus in the United States.

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K.

JAMA. 2003 Jan 8;289(2):179-86.

PMID:
12517228
9.

Modelling the structure of the fusion protein from human respiratory syncytial virus.

Smith BJ, Lawrence MC, Colman PM.

Protein Eng. 2002 May;15(5):365-71.

PMID:
12034856
11.

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF.

J Infect Dis. 1997 Nov;176(5):1215-24.

PMID:
9359721
12.

Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain.

Tao Y, Strelkov SV, Mesyanzhinov VV, Rossmann MG.

Structure. 1997 Jun 15;5(6):789-98.

13.

Shape complementarity at protein/protein interfaces.

Lawrence MC, Colman PM.

J Mol Biol. 1993 Dec 20;234(4):946-50.

PMID:
8263940
15.

Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

López JA, Andreu D, Carreño C, Whyte P, Taylor G, Melero JA.

J Gen Virol. 1993 Dec;74 ( Pt 12):2567-77.

PMID:
7506298
16.
17.

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

Arbiza J, Taylor G, López JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al.

J Gen Virol. 1992 Sep;73 ( Pt 9):2225-34.

PMID:
1383404

Supplemental Content

Support Center